NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

Start Free »

ICLR | NASDAQ

$165.85 -$4.14 | -2.44%

SIGNAL:

|2026-09-24 |F&G 56 |RSI 51.7

Add to favoritesFavorite

Company Overview:

Market Cap: $13.06B

Trailing PE: 296.2x

FWD PE *: 14.9x

Payout Ratio (TTM): —

52-Week Range: $66.57 - $203.91

* Forward PE is based on street estimates.

10 Year ICLR Performance Metrics:

Total Return (with DRIP): 116.6% (8.03% CAGR)

Total Return (no DRIP): 116.6% (8.03% CAGR)

Share Price: 114.4% (7.92% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $21,657

Total Return $ (with DRIP): $11,657

ICLR Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

ICLR Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

ICLR Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

ICLR - Revenue

ICLR Revenue CAGR:1Y: 2.29%2Y: -1.35%5Y: 18.82%10Y: 17.52%

ICLR - Earnings Per Share (EPS)

ICLR EPS CAGR:1Y: -59.13%2Y: -26.92%5Y: -7.39%10Y: -1.38%

ICLR - Net Income

🔓 See the full chart40% off right now · 7-day free trial

ICLR Net Income CAGR:1Y: -60.33%2Y: -29.71%5Y: -0.35%10Y: 1.74%

ICLR - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

ICLR EBITDA CAGR:1Y: -6.75%2Y: -13.01%5Y: 17.19%10Y: 11.99%

ICLR - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

ICLR Free Cash Flow CAGR:1Y: 87.25%2Y: 15.07%5Y: 15.64%10Y: 34.77%

ICLR - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

ICLR Free Cash Flow / Share CAGR:1Y: 90.27%2Y: 18.53%5Y: 7.01%10Y: 30.22%

ICLR - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

ICLR Operating Income CAGR:1Y: -7.17%2Y: -8.08%5Y: 11.46%10Y: 10.14%

ICLR - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

ICLR Gross Profit CAGR:1Y: -14.66%2Y: 0.25%5Y: 14.83%10Y: 10.75%

ICLR - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

ICLR Shares Outstanding CAGR:1Y: -2.73%2Y: -3.66%5Y: 7.71%10Y: 3.18%

ICLR - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

ICLR Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

ICLR - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

ICLR Stock-Based Comp CAGR:1Y: 21.02%2Y: 11.06%5Y: 16.83%10Y: 5.22%

ICLR - Expenses

🔓 See the full chart40% off right now · 7-day free trial

ICLR Expenses CAGR:1Y: 21.78%2Y: 8.20%5Y: 26.64%10Y: 13.18%

ICLR - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

ICLR - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

ICLR - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

ICLR - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

ICLR - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

ICLR - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

ICLR - Revenue by Segment

🔓 See the full chart40% off right now · 7-day free trial

ICLR Revenue CAGR:1Y: 2.29%2Y: -1.35%5Y: 18.82%10Y: 17.52%

ICLR - Revenue by Region

🔓 See the full chart40% off right now · 7-day free trial

ICLR Revenue CAGR:1Y: 2.29%2Y: -1.35%5Y: 18.82%10Y: 17.52%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

ICLR - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ICLR Actual Revenue CAGR:1Y: 2.29%2Y: -1.35%5Y: 18.82%10Y: 17.52%

ICLR - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ICLR Actual EPS CAGR:1Y: -59.13%2Y: -26.92%5Y: -7.39%10Y: -1.38%

ICLR - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ICLR Actual Net Income CAGR:1Y: -60.33%2Y: -29.71%5Y: -0.35%10Y: 1.74%

ICLR - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

ICLR Actual EBITDA CAGR:1Y: -6.75%2Y: -13.01%5Y: 17.19%10Y: 11.99%

Ratios, Profit Margins & Return on Capital:

ICLR - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

ICLR Net Profit Margin CAGR:1Y: -61.19%2Y: -28.73%5Y: -16.13%10Y: -13.42%

ICLR - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

ICLR Gross Profit Margin CAGR:1Y: -32.36%2Y: -8.50%5Y: -7.33%10Y: -7.72%

ICLR - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

ICLR Price to Earnings CAGR:1Y: 193.49%2Y: 1.82%5Y: 4.53%10Y: 11.29%

ICLR - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

ICLR Price To Sales Ratio CAGR:1Y: 13.22%2Y: -27.63%5Y: -12.42%10Y: -3.70%

ICLR - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

ICLR Return on Capital Employed CAGR:1Y: 4.59%2Y: -11.42%5Y: -19.30%10Y: -12.19%

ICLR - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

ICLR Return on Invested Capital CAGR:1Y: -25.17%2Y: -19.34%5Y: -22.17%10Y: -13.94%

Projected Future Returns & Dividends for ICLR

Based on past 10-year performance, here are ICLR growth metrics:

Share price CAGR of +7.92%
Dividend CAGR of +0%

Using ICLR CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	ICLR (DRIP)	ICLR - No DRIP
Current Price	$165.85	$165.85
Start Shares	60.30	60.30
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	60.30	60.30
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$165.85	$165.85
Total Dividends	$0	$0
Final Value	$10,000	$10,000

Estimated Future Value + Dividends - ICLR

NOTE: Above numbers are our estimate based on ICLR's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

ICON Public Limited Company (ICLR) had its IPO on 1998-05-15, and is traded on NASDAQ stock exchange.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

ICLR website: https://www.iconplc.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

DCF Model — ICLR

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $165.85

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →